Publications by authors named "M Traumann"
Purpose: No currently available phase III trial compared docetaxel vs. androgen receptor pathway inhibitors (ARPI) regarding cancer-control outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). Moreover, few is known about the effect of sequential therapies in mHSPC and subsequent metastatic castration resistant prostate cancer (mCRPC).
View Article and Find Full Text PDFHormonal agents administered for metastatic castration-resistant prostate cancer (mCRPC) may lead to osteoporosis, skeletal events, reduced quality of life, and even reduced overall survival (OS). Bone-modifying agents may prevent those events but their effect on cancer-control outcomes remains uncertain. Relying on our institutional tertiary-care database, we explored the effect of bone-modifying agents (bisphosphonates such as zoledronic acid and denosumab) on OS and progression-free survival in patients with mCRPC with at least 1 bone metastasis using Kaplan-Meyer estimates and Cox regression models.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on understanding how different metastatic sites (lymph nodes, bones, and visceral organs) affect outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC), specifically regarding progression-free survival (PFS) and overall survival (OS).
- Using data from the Frankfurt Metastatic Cancer Database, researchers classified 363 patients based on their metastatic sites and analyzed PFS and OS using Cox regression models.
- Results showed that M1c mCRPC patients have significantly worse outcomes, with higher risks for both progression and death compared to M1a patients, while M1a patients experienced the best outcomes overall.
Article Synopsis
- The study investigates the differences in overall survival (OS) between patients with metastatic hormone-sensitive prostate cancer (mHSPC) based on whether their condition was "De Novo" (newly diagnosed) or "secondary" (progressed from previous conditions), and their disease volume (high vs. low).
- The research used a database of 504 mHSPC patients, finding that those with De Novo high volume mHSPC had shorter time to develop metastatic castration resistant prostate cancer (mCRPC) and worse OS compared to secondary and low volume cases.
- The results highlight that patients with De Novo high volume mHSPC have a more challenging prognosis even when treated with intensified combination therapies, and this trend
Article Synopsis
- Biochemical recurrence (BCR) is when prostate-specific antigen (PSA) levels rise after prostate cancer treatment, and this study aimed to examine factors like age, body mass index (BMI), and prostate volume related to BCR post-radical prostatectomy (RP).
- Within a group of 821 patients who had RP from January 2014 to June 2023, the study analyzed their characteristics and found that only higher prostate volume was significantly linked to increased BCR rates, while age and BMI showed no significant association.
- The results suggest that patients with higher prostate volume should receive more careful monitoring after surgery due to their increased risk of BCR.